Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer - ASCO | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
ASCO
2022
·
USA
·
Oncology
Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer
Document
Analyser ce document
